- Biophytis has secured **non-dilutive public funding** from **EMBRAPII** in Brazil for its OBA Phase 2 trial of BIO101, which targets muscle wasting associated with obesity.  **[1768946_0001104659-25-089885_tm2526089d1_ex99-1.htm:0]** 
- The company also established agreements with two leading Brazilian clinical research centers, **FARMAVAX-UFMG** and **FMRP-USP**, which are crucial for recruiting **122 of the 164 planned patients** for the OBA trial.  **[1768946_0001104659-25-089885_tm2526089d1_ex99-1.htm:0]** 
- These developments are expected to **financially de-risk** the trial, **accelerate operations**, and enhance the program's scientific and strategic credibility, reducing the company's cash requirements.  **[1768946_0001104659-25-089885_tm2526089d1_ex99-1.htm:0]**

Biophytis Secures Brazilian Public Funding and Clinical Partnerships for Obesity Phase 2 Trial

- Biophytis SA has unveiled its **Phase 3 SARA trial strategy** for **BIO101**, targeting age-related sarcopenia, with plans to recruit **932 patients** primarily in **Asia (China and Japan)** and **Europe**.  **[1768946_0001104659-25-089342_tm2525887d1_ex99-1.htm:0]** 
- This trial is designed to be the **first Phase 3 ever conducted in sarcopenia**, addressing a substantial unmet medical need and commercial market estimated at over **65 million patients** across China, Japan, and Europe.  **[1768946_0001104659-25-089342_tm2525887d1_ex99-1.htm:0]** 
- The financing for the Phase 3 program will be achieved through **collaborations with regional pharmaceutical companies and local investors in Asia**, including non-dilutive private financing stakeholders.  **[1768946_0001104659-25-089342_tm2525887d1_ex99-1.htm:0]** **[1768946_0001104659-25-089342_tm2525887d1_ex99-1.htm:1]** 
- Trial initiation is expected in the **coming months in Europe**, with formal initiation in **China and Japan anticipated in 2026** after regulatory filings and partnership finalization.  **[1768946_0001104659-25-089342_tm2525887d1_ex99-1.htm:1]**

Biophytis (BPTSY)